Table 2 Univariate analysis of risk factors for LRR and DM in 1521 patients without PMRT
5-year LRR % (events) | p | 5-year DM % (events) | p | |
|---|---|---|---|---|
Treatment era | .521 | 0.446 | ||
1/2000–12/2009 | 7.2 (83) | 9.9 (137) | ||
1/2010–12/2014 | 6.0 (44) | 8.7 (66) | ||
Age (years) | .012 | 0.003 | ||
≤ 40 | 11.1 (29) | 14.2 (44) | ||
> 40 | 5.9 (98) | 8.5 (159) | ||
Tumor location | .003 | 0.025 | ||
Inner quadrant | 10.7 (42) | 11.5 (59) | ||
Other quadrants | 5.3 (82) | 8.5 (141) | ||
Unknown | ||||
Stage (AJCC 8th ed.) | < .001 | < 0.001 | ||
IA | 2.5 (18) | 4.9 (43) | ||
IB- IIA | 6.1 (60) | 8.1 (95) | ||
IIB- IIIA | 16.7 (49) | 21.9 (65) | ||
No. of nodes dissected | .144 | 0.134 | ||
< 10 | 10.3 (10) | 13.9 (14) | ||
≥ 10 | 6.4 (117) | 9.1 (189) | ||
No. of positive nodes | .001 | 0.059 | ||
1 | 5.7 (55) | 8.7 (102) | ||
2–3 | 7.9 (72) | 10.1 (101) | ||
Lympho-vascular invasion | .226 | 0.042 | ||
Yes | 7.7 (17) | 15.7 (28) | ||
No | 6.5 (110) | 8.6 (175) | ||
Histological grade | .044 | 0.461 | ||
I | 1.6 (1) | 9.3 (8) | ||
II | 6.1 (81) | 8.1 (128) | ||
III | 8.7 (45) | 11.9 (67) | ||
T stage | < .001 | < 0.001 | ||
T1 | 3.7 (35) | 6.8 (76) | ||
T2 | 9.7 (92) | 11.9 (127) | ||
Estrogen receptor | < .001 | < 0.001 | ||
Positive | 5.0 (81) | 6.7 (131) | ||
Negative | 12.0 (46) | 17.8 (72) | ||
Progesterone receptor | < .001 | < 0.001 | ||
Positive | 4.6 (74) | 6.4 (126) | ||
Negative | 13.1 (53) | 18.4 (77) | ||
HER2 | .685 | 0.519 | ||
Positive | 7.7 (9) | 8.4 (10) | ||
Negative | 6.6 (118) | 9.4 (193) |